Prostatic Neoplasms, Castration-Resistant
"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
Descriptor ID |
D064129
|
MeSH Number(s) |
C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
|
Concept/Terms |
Prostatic Neoplasms, Castration-Resistant- Prostatic Neoplasms, Castration-Resistant
- Castration-Resistant Prostatic Neoplasm
- Neoplasm, Castration-Resistant Prostatic
- Neoplasms, Castration-Resistant Prostatic
- Prostatic Neoplasm, Castration-Resistant
- Prostatic Neoplasms, Castration Resistant
- Androgen-Insensitive Prostatic Neoplasms
- Androgen Insensitive Prostatic Neoplasms
- Androgen-Resistant Prostatic Neoplasms
- Androgen Resistant Prostatic Neoplasms
- Prostatic Neoplasms, Hormone Refractory
- Hormone Refractory Prostatic Neoplasms
- Prostatic Neoplasms, Androgen-Independent
- Androgen-Independent Prostatic Neoplasm
- Neoplasm, Androgen-Independent Prostatic
- Neoplasms, Androgen-Independent Prostatic
- Prostatic Neoplasm, Androgen-Independent
- Prostatic Neoplasms, Androgen Independent
- Prostatic Neoplasms, Androgen-Insensitive
- Androgen-Insensitive Prostatic Neoplasm
- Neoplasm, Androgen-Insensitive Prostatic
- Neoplasms, Androgen-Insensitive Prostatic
- Prostatic Neoplasm, Androgen-Insensitive
- Prostatic Neoplasms, Androgen Insensitive
- Prostatic Neoplasms, Androgen-Resistant
- Androgen-Resistant Prostatic Neoplasm
- Neoplasm, Androgen-Resistant Prostatic
- Neoplasms, Androgen-Resistant Prostatic
- Prostatic Neoplasm, Androgen-Resistant
- Prostatic Neoplasms, Androgen Resistant
- Androgen-Independent Prostatic Neoplasms
- Androgen Independent Prostatic Neoplasms
- Castration-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
Prostatic Cancer, Castration-Resistant- Prostatic Cancer, Castration-Resistant
- Cancer, Castration-Resistant Prostatic
- Cancers, Castration-Resistant Prostatic
- Castration-Resistant Prostatic Cancers
- Prostatic Cancer, Castration Resistant
- Prostatic Cancers, Castration-Resistant
- Androgen-Insensitive Prostatic Cancer
- Androgen Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Androgen Resistant Prostatic Cancer
- Prostatic Cancer, Hormone Refractory
- Hormone Refractory Prostatic Cancer
- Prostatic Cancer, Androgen-Independent
- Androgen-Independent Prostatic Cancers
- Cancer, Androgen-Independent Prostatic
- Cancers, Androgen-Independent Prostatic
- Prostatic Cancer, Androgen Independent
- Prostatic Cancers, Androgen-Independent
- Prostatic Cancer, Androgen-Insensitive
- Androgen-Insensitive Prostatic Cancers
- Cancer, Androgen-Insensitive Prostatic
- Cancers, Androgen-Insensitive Prostatic
- Prostatic Cancer, Androgen Insensitive
- Prostatic Cancers, Androgen-Insensitive
- Prostatic Cancer, Androgen-Resistant
- Androgen-Resistant Prostatic Cancers
- Cancer, Androgen-Resistant Prostatic
- Cancers, Androgen-Resistant Prostatic
- Prostatic Cancer, Androgen Resistant
- Prostatic Cancers, Androgen-Resistant
- Androgen-Independent Prostatic Cancer
- Androgen Independent Prostatic Cancer
- Castration-Resistant Prostatic Cancer
- Castration Resistant Prostatic Cancer
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".
This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2013 | 6 | 2 | 8 |
2014 | 18 | 4 | 22 |
2015 | 14 | 1 | 15 |
2016 | 24 | 0 | 24 |
2017 | 11 | 3 | 14 |
2018 | 16 | 2 | 18 |
2019 | 12 | 1 | 13 |
2020 | 15 | 0 | 15 |
2021 | 18 | 0 | 18 |
2022 | 8 | 0 | 8 |
2023 | 18 | 0 | 18 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. Cancer Res. 2024 03 04; 84(5):703-724.
-
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res Treat. 2024 Apr; 204(2):249-259.
-
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res. 2023 11 01; 29(21):4464-4478.
-
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 10 31; 42(10):113221.
-
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023 10; 192:113249.
-
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clin Cancer Res. 2023 07 05; 29(13):2426-2434.
-
Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat Commun. 2023 06 09; 14(1):3357.
-
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023 08 01; 41(22):3839-3850.